Literature DB >> 9546426

The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.

R Pinkas-Kramarski1, A E Lenferink, S S Bacus, L Lyass, M L van de Poll, L N Klapper, E Tzahar, M Sela, E J van Zoelen, Y Yarden.   

Abstract

The ErbB-1 receptor tyrosine kinase binds to six different growth factors, whose prototype is the epidermal growth factor (EGF). Two homologous epithelial receptors, ErbB-3 and ErbB-4, bind all isoforms of another family of growth factors, the Neu differentiation factors (NDFs/neuregulins). The fourth member of the ErbB family, ErbB-2, acts as the preferred heterodimeric partner of ligand-occupied complexes of the three other ErbB proteins. Here we report that at high concentrations, EGF can induce cell growth and differentiation in the absence of ErbB-1. This function is shared by betacellulin, but not by three other ligands, including the transforming growth factor alpha (TGFalpha). The functional receptor was identified as a heterodimer between ErbB-3 and ErbB-2, a previously identified oncogenic complex. When singly expressed, neither ErbB-3 nor ErbB-2 can mediate signaling by EGF. In addition, when co-expressed, blocking either receptor by using site-specific antibodies inhibited EGF and betacellulin activities, indicating strict cooperativity between ErbB-3 and ErbB-2. Through analysis of chimeras between EGF and TGFalpha, we identified the middle portion of EGF (loop B) as the site that enables activation of ErbB-2/ErbB-3. In conclusion, cooperative and promiscuous binding of stroma-derived growth factors by the epithelium-expressed ErbB-2/ErbB-3 heterodimer may be significant to cancer development. The mechanistic implications of our results for a model that attributes receptor dimerization to ligand bivalency, as well as to a recently proposed mechanism of secondary dimerization, are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9546426     DOI: 10.1038/sj.onc.1201642

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.

Authors:  H Waterman; I Alroy; S Strano; R Seger; Y Yarden
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.

Authors:  L N Klapper; S Glathe; N Vaisman; N E Hynes; G C Andrews; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

3.  Identification of novel cell-adhesion molecules in peripheral nerves using a signal-sequence trap.

Authors:  Ivo Spiegel; Konstantin Adamsky; Menahem Eisenbach; Yael Eshed; Adrian Spiegel; Rhona Mirsky; Steven S Scherer; Elior Peles
Journal:  Neuron Glia Biol       Date:  2006-02

4.  Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network.

Authors:  E Tzahar; J D Moyer; H Waterman; E G Barbacci; J Bao; G Levkowitz; M Shelly; S Strano; R Pinkas-Kramarski; J H Pierce; G C Andrews; Y Yarden
Journal:  EMBO J       Date:  1998-10-15       Impact factor: 11.598

5.  Identification of betacellulin as a major peptide growth factor in milk: purification, characterization and molecular cloning of bovine betacellulin.

Authors:  A J Dunbar; I K Priebe; D A Belford; C Goddard
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

6.  Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.

Authors:  Naoki Kanomata; Junichi Kurebayashi; Takuya Moriya
Journal:  Med Mol Morphol       Date:  2018-10-13       Impact factor: 2.309

7.  Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry.

Authors:  F J Esteva; G N Hortobagyi; A A Sahin; T L Smith; D M Chin; S Y Liang; L Pusztai; A U Buzdar; S S Bacus
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 8.  The use of nanoparticulates to treat breast cancer.

Authors:  Xiaomeng Tang; Welley S Loc; Cheng Dong; Gail L Matters; Peter J Butler; Mark Kester; Craig Meyers; Yixing Jiang; James H Adair
Journal:  Nanomedicine (Lond)       Date:  2017-09-04       Impact factor: 5.307

Review 9.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

10.  ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.

Authors:  R Pinkas-Kramarski; M Shelly; B C Guarino; L M Wang; L Lyass; I Alroy; M Alimandi; A Kuo; J D Moyer; S Lavi; M Eisenstein; B J Ratzkin; R Seger; S S Bacus; J H Pierce; G C Andrews; Y Yarden; M Alamandi
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.